GSK-2302025A

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGSK-2302025A

Drug Alias NamePRAME Antigen Specific Cancer Immunotherapeutic-Melanoma,PRAME-ASCI-melanomaGSK-2302025A

ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaPolandRussian Federation +[6]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsMelanoma

ATC CodeN/A